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Economics is known as the dismal science: perhaps because it
draws attention to the less pleasant consequences of our
actions. If I have £1.000 in the bank I can afford a holiday in
the Caribbean or I could have the leaking roof mended. I
cannot. since my resources are finite, afford both. If I choose
the holiday then, by economic definition, the opportunity
cost of my visit to the Caribbean is the unrepaired roof. The
damp patch on the ceiling will be a constant reminder of the
choice I made. The concept of opportunity cost is simple: if
resources are finite and there are mutually exclusive com-
peting options for the use of those resources then the option
that is not chosen represents the opportunity cost of the
chosen option.
The treatment of cancer can impose opportunity costs and
these are not necessarily financial. For many patients the
finite resource that is of concern is time, time which may be
beyond price. Patients who receive protracted courses of
radiotherapy or chemotherapy are unable to do things that
they might prefer to do: spend time at home with their
families; take holidays: simply do nothing. When treatment is
effective. and survival is long. then the opportunity cost of
time spent on treatment is. in relative terms. negligible. When
survival is short and treatment is only palliative then the
opportunity cost of time spent on treatment may represent a
considerable proportion of remaining lifespan. Data from
two recent randomised trials (Arriagada et al.. 1991: Dillman
et al.. 1990) of radiotherapy ± chemotherapy for inoperable
non-small cell lung cancer illustrate this latter point.
In the Amragada study nearly 25% of patients randomised
to treatment with radiotherapy ± chemotherapy spent all
their survival time on active treatment. In the study by
Dillman et al.. using more stringent cnteria for entry and
shorter overall treatment time. the corresponding figure was
5%.
Thirty one per cent of patients in Arriagada's study treated
with radiotherapy alone spent less than 10% of their total
survival time on treatment. the corresponding figure for
patients treated with combined therapy was 6%; the corre-
sponding figures for the study by Dillman et al. were 36%
and 25%.
Similar analyses can be performed using data from trials
using radiotherapy alone for the treatment of inoperable non
small-cell lung cancer (Report to the Medical Research
Council by its Lung Cancer Working Party. 1991; Perez et
al.. 1987). The MRC study compared 1.700 cGy in two
fractions with 3.000 cGy in ten fractions. In the RTOG study
(Perez et al.. 1987) 4.000 cGy in four weeks was compared
with 6.000cGy in 6 weeks. In the MRC study over 50% of
patients. in both arms, spent less than 10% of their total
survival time on treatment compared with only 35 to 40% of
patients in the RTOG study. Less than 5% of patients in any
of the treatment arms in either study spent their entire sur-
vival time on treatment.
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Treating incurable disease unto death is patently unaccep-
table. Patients who spend the last few weeks of their lives
undergoing active treatment sacrifice autonomy. Timetables
are set by hospital visits and treatment schedules. The oppor-
tunity cost, for such patients, is the ability to use their last
days as they would wish. These costs cannot be recouped.
Quality of life measures do not explicitly incorporate the
concept of opportunity cost. The assumption is that, if
patients feel well, have a positive attitude, and have adequate
social support, then their quality oflife is excellent. However,
if. because of the disruptions associated with treatment,
patients cannot use the time when they are feeling well in the
ways that they would wish, then their wishes and aspirations
are not, in fact, being matched by reality. By Calman's
definition their quality of life is thereby impaired (Calman.
1984). In making therapeutic decisions the opportunity costs
of treatment are often overlooked. This partly reflects our
training and perceived role: our first reaction is to intervene,
to act, rather than to refrain from action. We emphasise the
possible benefits from intervention and belittle the disadvant-
ages. Another factor is also important.
Feinstein has defined and discussed the 'chagrin factor'
(Feinstein. 1985): doctors are reluctant to withhold active
treatment from patients because they wish to avoid the chag-
rin associated with allowing the death of a patient who, given
treatment. might have survived. In an extreme case 98
patients might be treated ineffectively simply to prevent two
deaths. If treatment is free from toxicity and incurs no
opportunity cost then there is no problem. The 98 patients
treated ineffectively pay no penalty. When treatment is toxic
and erodes the time that is left then another form ofchagrin
emerges - that associated with the distress caused to the 98 in
order that the two may be saved. Opportunity cost is an
important contributor to this second form of chagrin.
There is no simple way to measure the opportunity costs of
treatment. The data presented previously represent a strictly
quantitative approach. but suffer from the obvious dis-
advantage that days on treatment are simply counted. No
qualitative weightings are applied. Such an analysis might be
useful at the planning stage of a clinical trial since. based on
a priori assumptions. it would give some indication of the
opportunity costs of an experimental therapy.
A crude financial approach would simply be to ask
patients how much they would be prepared to pay if. by
some means, they could purchase freedom from time spent
on treatment. This is unlikely to provide a useful measure of
opportunity costs since patients will evaluate any costs in
relation to their existing means, and these will vary widely.
The sums allocated would also be strongly influenced by the
perceived physical distress associated with treatment and so
would not solely reflect opportunity cost.
A loose estimate not of opportunity cost itself, but of
patients' attitudes towards it, would be, before treatment was
started. to ask patients what percentage of their total survival
they would be prepared to spend undergoing active treat-
ment. The problem here is that choice would be influenced
by the duration of expected survival. The interpretation. by
patients, of any data on survival presented to them will be
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prone to all sorts of biases. and these biases will vitiate anv
possible conclusions concerning their attitudes as to what
constitutes an acceptable proportion of survival time to be
spent on treatment.
The TWiST concept (Goldhirsch et al.. 1989). time without
symptoms of disease and toxicitv. introduced by the Ludwig
Breast Cancer Study Group does. by implication. include
some estimate of opportunity cost. It may be extremely
useful in studies of adjuvant therapy for breast cancer but is
not really applicable to conditions such as lung cancer. where
survival is short and where patients may never be completely
free from symptoms.
Opportunity costs could be measured using linear analogue
self assessment (LASA) scales or categorical scales based on
a question such as: 'Please indicate to what extent your life
has been disrupted as a direct result of your treatment'. Even
this approach will give rise to problems of attribution since it
is difficult to separate disruption caused directly by illness
from that caused by treatment. Nevertheless, it offers a fairly
straightforward measure that could easily by incorporated
into existing multi-item questionnaires designed to measure
quality of life.
The opportunitv cost of active treatment should be con-
sidered when making decisions concerning the management
of patients with cancer: particularly when survival may be
short. It is difficult to quantify and its assessment should
provide an interesting challenge for future clinical studies.
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